Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diclofenac + orphenadrine
- Development stage
- Unknown
- Lead developer
- Sanjivani Parenteral
- Modality
- Small Molecules
- Administration
- Intramuscular, Intravenous, Parenteral
01
Overview
Miofedrol Relex is a fixed-dose combination of the non-steroidal anti-inflammatory drug (NSAID) diclofenac sodium and the centrally acting skeletal muscle relaxant orphenadrine citrate. Developed by Sanjivani Parenteral, it is formulated as an injection for intramuscular or intravenous administration. Diclofenac acts by inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis to alleviate pain and inflammation. Orphenadrine acts as an antagonist at histamine H1, muscarinic acetylcholine, and NMDA receptors, providing muscle relaxation and central analgesic effects. Miofedrol Relex is approved and marketed for the treatment of acute pain, inflammation, and muscle spasms associated with musculoskeletal disorders.
- Brand names
- Miofedrol RelaksMiofedrol RelexNeodolpasseRedex Plus
- Other names
- diclofenac and orphenadrinediclofenac sodium + orphenadrine citrate
02
Targets
GRIN1 (NMDA receptor subunit 1)GRIN2D (Glutamate receptor ionotropic NMDA subunit 2D)HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)M1 (Muscarinic acetylcholine receptor M1)SCN10A (Sodium channel protein type X alpha subunit)
Beyond the preview
Go deeper on diclofenac + orphenadrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diclofenac + orphenadrine.